Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGF-Endoret in Neurotrophic Keratitis
NCT02707120Phase 4Withdrawn
- Sponsor
- BTI Biotechnology Institute
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 4 trial of PRGF-Endoret in neurotrophic keratitis (NK), sponsored by BTI Biotechnology Institute. Planned start Jan 2018; status: withdrawn.
02
Drugs
PRGF-Endoret
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on NCT02707120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707120.